BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential

Core Viewpoint - Apellis Pharmaceuticals Inc. is recognized as a high short interest stock with significant upside potential, particularly due to the promising commercial prospects of its drug Empaveli in treating rare kidney diseases [1]. Group 1: Analyst Ratings and Price Targets - Bank of America upgraded Apellis to Buy from Neutral with an unchanged price target of $28, emphasizing the market's undervaluation of Empaveli's commercial prospects [1]. - Wells Fargo reduced its price target for Apellis to $26 from $29 while maintaining an Overweight rating, citing a slower-than-expected commercial ramp for Empaveli in specific indications [2]. Group 2: Revenue Estimates and Market Potential - Bank of America has cut its revenue estimates for 2026–2030 by 20% to 50% to reflect a more gradual adoption curve for Empaveli, while estimates for another drug, Syfovre, remain largely unchanged [3]. - The initial 5% penetration of the 5,000-patient US market for Empaveli has led analysts to forecast continued financial upside as the drug expands into new indications [1]. Group 3: Company Overview - Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic compounds to address diseases with high unmet needs [4].